Migraine Awareness Month
Migraine Awareness Month is an International Event held every year in June and is organised in Australia by Migraine Australia, a national patient advocacy organisation founded to support all Australians living with migraine and their families. Migraine Australia
UpToDate
Diagnosis
General
Treatment
Cochrane library
Articles
Diagnosis
Research
Treatment
E-books
E-journals
__________________________________________________________________________________
Articles
Diagnosis
Population-based characterization of menstrual migraine and proposed diagnostic criteria
In this case-control study, menstrual migraine (MM) in the general population had clinical characteristics that were quantitively different from those of non-MM. Detailed descriptive data and suggested improved diagnostic criteria for pure MM and menstrually related migraine were provided. JAMA 15 May 2023
Cervical cord infarction mimicking migraine in a patient with vertebral artery dissection
Lessons from practice
MJA 20 February 2023
Verification of a clinical decision support system for the diagnosis of headache disorders based on patient–computer interactions: a multi-center study
The clinical decision support system (CDSS 2.0) achieved high diagnostic accuracy for most primary and some secondary headaches. Human–computer conversation data were well integrated into the diagnostic process, and the system was well accepted by patients. The follow-up process and doctor–client interactions will be future areas of research for the development of CDSS for headaches. Journal of headache and pain 23 May 2023
Abnormalities in EEG as migraine marker: a mini review
The aim of this study is to review the use of EEG in detecting migraine in past and recent investigations. Journal of biological studies 10 May 2023
__________________________________________________________________________________
Research
Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: randomized controlled trial
The H3-L6 and H3 interventions altered bioactive mediators implicated in headache pathogenesis and decreased frequency and severity of headaches, but did not significantly improve quality of life. BMJ 1 July 2021
Manual acupuncture versus sham acupuncture and usual care for prophylaxis of episodic migraine without aura: multicentre, randomised clinical trial
Twenty sessions of manual acupuncture was superior to sham acupuncture and usual care for the prophylaxis of episodic migraine without aura. These results support the use of manual acupuncture in patients who are reluctant to use prophylactic drugs or when prophylactic drugs are ineffective, and it should be considered in future guidelines. BMJ 25 March 2020
Anxiety and depressive symptoms and disorders in children and adolescents with migraine: A systematic review and meta-analysis
In this study, children and adolescents with migraine were more likely to experience internalizing symptoms and disorders compared with their peers without migraine; screening for these symptoms and disorders in clinical practice may be beneficial. JAMA 31 October 2022
Association between Meniere Disease and Migraine
The study results suggest that clinical management of MD can be improved by considering the possible comorbidity of migraine. Novel therapeutic agents could be developed based on the reciprocal association between the 2 diseases. JAMA 7 April 2022
Assessment of Erenumab safety and efficacy in patients with Migraine with and without aura: A secondary analysis of randomized clinical trials
Results of this secondary analysis of 4 randomized clinical trials showed reduced migraine frequency and AMSM days with erenumab treatment in patients with migraine with and without a history of aura. The findings support the efficacy and safety of using erenumab in this patient population. JAMA 20 December 2021
Neurological and psychiatric comorbidities of migraine: Concepts and future perspectives
These comorbid conditions in migraine with distinct pathophysiological mechanisms have important implications for best treatment choices and may provide clues for future approaches. Cephalalgia 8 June 2023
Association between migraine and Alzheimer’s disease: a nationwide cohort study
results suggest that individuals with a migraine history are more susceptible to Alzheimer’s disease than those without a migraine history. Additionally, these associations were more significant in younger and obese individuals with migraine than in individuals without migraine. Frontiers in aging neuroscience 25 May 2023
__________________________________________________________________________________
Treatment
Management of chronic migraine
Chronic migraine is a neurologic disorder associated with considerable disability, lost productivity, and a profound economic burden worldwide. The past five years have seen a dramatic expansion in new treatments for this often challenging condition, among them calcitonin gene related peptide antagonists and neuromodulatory devices. This review outlines the epidemiology of and diagnostic criteria and risk factors for chronic migraine. It discusses evidence based drug and non-drug treatments, their advantages and disadvantages, and the principles of patient centered care for adults with chronic migraine, with attention to differential diagnosis and comorbidities, clinical reasoning, initiation and monitoring, cost, and availability. It discusses the international guidelines on drug treatment for chronic migraine and evaluates non-drug treatments including behavioral and complementary therapies and lifestyle modifications. Finally, it discusses the management of chronic migraine in special populations, including pediatrics, pregnancy, and older people, and considers future questions and emerging research in the field. BMJ 10 October 2023
Primary headache drug treatment in emergency departments in Australia and New Zealand
Treating acute headache begins at home and continues, if necessary, in the emergency department (ED). Drug treatment is heterogenous, and understanding the determinants of prescribing could help appropriate medication choices. This article therefore assessed the predictors of prescribing in Australian and New Zealand EDs for people with primary headache. MJA 22 August 2022
Atogepant for the preventive treatment of migraine
Oral atogepant once daily was effective in reducing the number of migraine days and headache days over a period of 12 weeks. Adverse events included constipation and nausea. Longer and larger trials are needed to determine the effect and safety of atogepant for migraine prevention. NEJM 19 August 2021
Behavioral treatment for migraine prophylaxis in adults: Moderator analysis of a randomized controlled trial
These findings contribute to an individualized treatment selection and suggest that preference for complex behavioral treatment (migraine-specific cognitive-behavioral therapy) should be given to patients with high headache-related disability, increased anxiety, or a comorbid mental disorder. . Cephalalgia 8 June 2023
__________________________________________________________________________________
This is just a sample of the e-books the library subscribes to – you will need your library login
__________________________________________________________________________________
This is just a sample of the journals the library subscribes to – you will need your library login
__________________________________________________________________________________
Missed out on a previous awareness week? You can now see previous awareness weeks here.
